Skip to main content
. Author manuscript; available in PMC: 2016 Oct 1.
Published in final edited form as: Mol Carcinog. 2014 May 17;54(10):1096–1109. doi: 10.1002/mc.22179

Figure 1. Berberine treatment decreases colitis associated inflammation and aberrant proliferation.

Figure 1

Immunohistochemistry shows berberine reduced (A) CD-45+ leucocyte infiltration, at day 28 and (B) Ki-67+ aberrant proliferation and (C) COX-2 expression at day 70 post-AOM/DSS. Photomicrographs depict a representative section of colon with 5 mice in each group used for analysis. (D) Ki-67 expression quantification from immune-stain at day 70. P value <0.05 was considered statistically significant.